Skip to main content

Table 1 Baseline characteristics of study participants according to quartiles of eosinophil-to-monocyte ratio (EMR)

From: Eosinophil-to-monocyte ratio is a potential biomarker in the prediction of functional outcome among patients with acute ischemic stroke

Characteristics Q1 Q2 Q3 Q4 p value
No. of patients 125 135 130 131  
Age, years, mean (SD) 72.54 (13.50) 70.09 (12.48) 67.58 (12.64) 67.59 (13.96) 0.006
Female, (%) 64 (51.20%) 69 (51.11%) 50 (38.46%) 49 (37.40%) 0.026
Hypertension, (%) 113 (90.40%) 109 (80.74%) 113 (86.92%) 110 (83.97%) 0.150
Diabetes, % 34 (27.20%) 31 (22.96%) 34 (26.15%) 28 (21.37%) 0.671
Hyperlipidemia, % 36 (28.80%) 53 (39.26%) 55 (42.31%) 65 (49.62%) 0.008
Previous stroke, % 26 (20.80%) 28 (20.74%) 21 (16.15%) 21 (16.03%) 0.594
Coronary heart disease, % 16 (12.80%) 10 (7.41%) 14 (10.77%) 11 (8.40%) 0.461
Atrial fibrillation, % 26 (20.80%) 25 (18.52%) 19 (14.62%) 16 (12.21%) 0.245
Current cigarette smoking, % 14 (11.20%) 8 (5.93%) 19 (14.62%) 13 (9.92%) 0.138
NIHSS, median (IQR) 4 (2–8) 4 (2–6) 3 (1–6) 2 (1–6) 0.005
Premorbid mRS score, median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.293
Stroke subtypes 0.006
 Large artery atherosclerosis 40 (32.00%) 61 (45.19%) 48 (36.92%) 39 (29.77%)  
 Cardioembolic stroke 21 (16.80%) 22 (16.30%) 17 (13.08%) 17 (12.98%)  
 Small artery disease 59 (47.20%) 52 (38.52%) 64 (49.23%) 75 (57.25%)  
 Other etiology/unknown 5 (4.00%) 0 (0.00%) 1 (0.77%) 0 (0.00%)  
IV rtPA, % 7 (5.60%) 13 (9.63%) 9 (6.92%) 16 (12.21%) 0.237
Proton pump inhibitors, % 56 (44.80%) 54 (40.00%) 59 (45.38%) 44 (33.59%) 0.186
Triglyceride, mmol/L, median (IQR) 1.20 (0.89–1.60) 1.38 (1.00–1.82) 1.40 (0.94–1.92) 1.52 (1.06–2.38) 0.005
Total cholesterol, mmol/L, mean (SD) 4.77 (1.06) 4.99 (1.18) 4.92 (1.37) 5.00 (1.04) 0.364
High-density lipoprotein cholesterol, mmol/L, mean (SD) 1.36 (0.35) 1.34 (0.39) 1.28 (0.37) 1.24 (0.37) 0.035
Low-density lipoprotein cholesterol, mmol/L, mean (SD) 2.37 (0.70) 2.52 (0.74) 2.48 (0.82) 2.53 (0.70) 0.290
EMR, median (IQR) 0.04 (0.01–0.05) 0.12 (0.10–0.15) 0.26 (0.21–0.30) 0.49 (0.40–0.76) < 0.001
Poor outcome 65 (52.00%) 53 (39.26%) 34 (26.15%) 29 (22.14%) < 0.001
  1. EMR eosinophil-to-monocyte ratio, IQR interquartile range, IV rtPA intravenous recombinant tissue plasminogen activator, NIHSS National Institutes of Health Stroke Scale